They were referring to this qtr, and in connection with...

They were referring to this qtr, and in connection with negotiations. This is worth consideration. Have they ever before bothered to mention o/s travel?
To my mind this suggests one or more parties have examined the product/s, and are currently finishing Due Diligence. Any prospective partner or licensee will do thorough DD including on MM. It will be him going over to meet some big business bosses; a necessary formality.
Corr, who also did his DD on Monsour on behalf of the Inov8 fund prior to investing, will probably be directly involved also. If not he'll still be all over it as he's familiar with all this, and knows how to compete on equal terms with big business in negotiations. It's likely interested parties already know of Corr, and his presence as a Director will be a major factor in their interest in Analytica Medical being piqued.
The timing of this since Navigant began suits this scenario. So we have a vague idea of where we're at imo; good progress but with months yet of negotiating, proposals, lawyers and more lawyers, back and forth.

I suspect many prospective retail share buyers could wait thinking no catalysts till later in the year. Good luck with that fence-sitters. CE and FDA approvals for the pop indication to come; also a deal with the burette could well come considerably earlier due to it being more straightforward.
And there's no pressing cash problem.
It's happening.